These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
464 related articles for article (PubMed ID: 30593393)
1. Retroperitoneal fibrosis. Steroid treatment response seems to depend on its association to IgG4 related disease. Soriano Rios A; Paredes H; Hernández-Calleros J; Uscanga-Domínguez L; Peláez-Luna M Med Hypotheses; 2019 Jan; 122():120-123. PubMed ID: 30593393 [TBL] [Abstract][Full Text] [Related]
2. [Clinical Evaluation of Diagnostic and Treatment Protocol of Idiopathic Retroperitoneal Fibrosis Incorporating Consideration of Possible IgG4-Related Disease]. Iyoki T; Maehana T; Tanaka T; Yamamoto M; Takahashi H; Masumori N Hinyokika Kiyo; 2017 Nov; 63(11):449-454. PubMed ID: 29232794 [TBL] [Abstract][Full Text] [Related]
3. Relapse patterns and predictors of IgG4-related diseases involved with autoimmune pancreatitis: A single-center retrospective study of 115 patients. Miki M; Fujimori N; Oono T; Kawabe K; Ohno A; Matsumoto K; Teramatsu K; Tachibana Y; Ogawa Y J Dig Dis; 2019 Mar; 20(3):152-158. PubMed ID: 30701685 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of tofacitinib monotherapy for patients with IgG4-RD or idiopathic retroperitoneal fibrosis. Cao X; Li S; Wan J; Yu Z; Dong G; Zhou W Clin Exp Rheumatol; 2024 Sep; 42(9):1736-1743. PubMed ID: 38530663 [TBL] [Abstract][Full Text] [Related]
5. Idiopathic vs. secondary retroperitoneal fibrosis: a clinicopathological study of 12 cases, with emphasis to possible relationship to IgG4-related disease. Laco J; Podhola M; Kamarádová K; Novák I; Dobeš D; Broďák M; Hácová M; Ryška A Virchows Arch; 2013 Nov; 463(5):721-30. PubMed ID: 24052251 [TBL] [Abstract][Full Text] [Related]
6. Retroperitoneal fibrosis associated with immunoglobulin G4-related disease. Fujimori N; Ito T; Igarashi H; Oono T; Nakamura T; Niina Y; Hijioka M; Lee L; Uchida M; Takayanagi R World J Gastroenterol; 2013 Jan; 19(1):35-41. PubMed ID: 23326160 [TBL] [Abstract][Full Text] [Related]
7. Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Zen Y; Onodera M; Inoue D; Kitao A; Matsui O; Nohara T; Namiki M; Kasashima S; Kawashima A; Matsumoto Y; Katayanagi K; Murata T; Ishizawa S; Hosaka N; Kuriki K; Nakanuma Y Am J Surg Pathol; 2009 Dec; 33(12):1833-9. PubMed ID: 19950407 [TBL] [Abstract][Full Text] [Related]
8. High-throughput RNA sequencing reveals distinct gene signatures in active IgG4-related disease. Higgs BW; Liu Y; Guo J; Sebastian Y; Morehouse C; Zhu W; Ren L; Liu M; Du Y; Yu G; Dong L; Hua H; Wei P; Wang Y; Wang Z; Yao Y; Li ZG Sci Rep; 2017 Dec; 7(1):17567. PubMed ID: 29242501 [TBL] [Abstract][Full Text] [Related]
9. IgG4-related retroperitoneal fibrosis: a newly characterized disease. Lian L; Wang C; Tian JL Int J Rheum Dis; 2016 Nov; 19(11):1049-1055. PubMed ID: 27125330 [TBL] [Abstract][Full Text] [Related]
10. IgG4-related uveitis. A French cohort and literature review. Stuchfield-Denby E; De Sainte Marie B; Hie M; Hatchuel Y; Gerber A; Bencheikh S; Pugnet G; Groh M; Farhat MM; Urbina D; Ebbo M; Schleinitz N Semin Arthritis Rheum; 2024 Feb; 64():152278. PubMed ID: 38000318 [TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin G4-related retroperitoneal fibrosis. Angarola E; Valeo Chulvi M; Peuchot V; García Rivello H; Jauk F Medicina (B Aires); 2022; 82(1):91-98. PubMed ID: 35037866 [TBL] [Abstract][Full Text] [Related]
14. Retroperitoneal and aortic manifestations of immunoglobulin G4-related disease. Zen Y; Kasashima S; Inoue D Semin Diagn Pathol; 2012 Nov; 29(4):212-8. PubMed ID: 23068300 [TBL] [Abstract][Full Text] [Related]
15. [Mycophenolate mofetil combined with steroids: new experiences in the treatment of idiopathic retroperitoneal fibrosis]. Obrencević K; Jovanović D; Kovacević Z; Hrvacević R; Ignjatović L; Mijusković M Vojnosanit Pregl; 2007 Jun; 64(6):385-90. PubMed ID: 17687942 [TBL] [Abstract][Full Text] [Related]
16. [Successful therapy of retroperitoneal fibrosis due to IgG4-related disease with rituximab, cyclophosphamide and glucocorticoids followed by maintenance therapy wit ritutixmab]. Adam Z; Čermák A; Petrášová H; Řehák Z; Koukalová R; Fojtík Z; Pour L; Boichuk I; Krejčí M; Král Z; Benda P Vnitr Lek; 2023; 69(E-3):4-15. PubMed ID: 37468330 [TBL] [Abstract][Full Text] [Related]
17. A Review on The Role of Environmental Exposures in IgG4-Related Diseases. Grasso C; Giacchero F; Crivellari S; Bertolotti M; Maconi A Curr Environ Health Rep; 2023 Sep; 10(3):303-311. PubMed ID: 37314670 [TBL] [Abstract][Full Text] [Related]
18. Addition of second-line steroid sparing immunosuppressants like mycophenolate mofetil improves outcome of Immunoglobulin G4-related disease (IgG4-RD): a series from a tertiary care teaching hospital in South India. Gupta N; Mathew J; Mohan H; Chowdhury SD; Kurien RT; Christopher DJ; Thangakunam B; Alexander M; Sivadasan A; Tamilarasi V; Valson AT; Gowri M; Kabeerdoss J; Danda D Rheumatol Int; 2018 Feb; 38(2):203-209. PubMed ID: 28550399 [TBL] [Abstract][Full Text] [Related]
19. Clinical manifestations, clinical course, and outcomes of immunoglobulin G4-related disease. Phaopraphat K; Ngamjanyaporn P; Narongroeknawin P; Kasitanon N; Katchamart W Int J Rheum Dis; 2020 Nov; 23(11):1468-1473. PubMed ID: 32808722 [TBL] [Abstract][Full Text] [Related]
20. The treatment outcomes in IgG4-related disease. Karim AF; Bansie RD; Rombach SM; Paridaens D; Verdijk RM; van Hagen PM; Van Laar JAM Neth J Med; 2018 Aug; 76(6):275-285. PubMed ID: 30152392 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]